Publications by authors named "Daniel Gusenleitner"

Claim this Profile
I
Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle-Based Blood Test: Performance in a Training and Verification Cohort.
Emily S Winn-Deen, Laura T Bortolin, Daniel Gusenleitner, Kelly M Biette, Karen Copeland

J Mol Diagn· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S Hong, Lillian L Siu, Daniel Gusenleitner

Oncoimmunology· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, Paulien Kaptein, Lea J Albrecht, Daniel Gusenleitner

Nat Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, Paulien Kaptein, Lea J Albrecht, Daniel Gusenleitner

Nat Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
Hussein A Tawbi, Caroline Robert, Jan C Brase, Daniel Gusenleitner, Eduard Gasal

J Immunother Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
Patrick Schöffski, Daniel S W Tan, Miguel Martín, María Ochoa-de-Olza, John Sarantopoulos, Daniel Gusenleitner

J Immunother Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib.
Jan C Brase, Robert F H Walter, Alexander Savchenko, Daniel Gusenleitner, James Garrett

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
Gabriel K Griffin, Jason L Weirather, Margaretha G M Roemer, Mikel Lipschitz, Alyssa Kelley, Daniel Gusenleitner

Blood· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, Mario Mandalà, Paul D Nathan, Daniel Gusenleitner

Nat Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
Reinhard Dummer, Jan C Brase, James Garrett, Catarina D Campbell, Eduard Gasal, Daniel Gusenleitner

Lancet Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Scott J Rodig, Daniel Gusenleitner, Donald G Jackson, Evisa Gjini, Anita Giobbie-Hurder

Sci Transl Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.
Sachet A Shukla, Pavan Bachireddy, Bastian Schilling, Christina Galonska, Qian Zhan, Daniel Gusenleitner

Cell· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients.
Priyanka B Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner, Anita Giobbie-Hurder, Mariano Severgnini

J Immunother Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Christopher D Carey, Daniel Gusenleitner, Mikel Lipschitz, Margaretha G M Roemer, Edward C Stack

Blood· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.
Olga Novikov, Zhongyan Wang, Elizabeth A Stanford, Ashley J Parks, Alejandra Ramirez-Cardenas, Daniel Gusenleitner

Mol Pharmacol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities.
Elizabeth A Morgan, M Patrick Sweeney, Tamiwe Tomoka, Nadja Kopp, Daniel Gusenleitner

Blood Adv· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
Bjoern Chapuy, Hongwei Cheng, Akira Watahiki, Matthew D Ducar, Yuxiang Tan, Daniel Gusenleitner

Blood· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Bjoern Chapuy, Margaretha G M Roemer, Chip Stewart, Yuxiang Tan, Ryan P Abo, Daniel Gusenleitner

Blood· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathways.
Ying Shen, Mumtahena Rahman, Stephen R Piccolo, Daniel Gusenleitner, Nader N El-Chaar

Bioinformatics· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action.
Daniel Gusenleitner, Scott S Auerbach, Tisha Melia, Harold F Gómez, David H Sherr

PLoS One· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Christopher D Carey, Daniel Gusenleitner, Bjoern Chapuy, Alexandra E Kovach, Michael J Kluk

J Mol Diagn· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RamiGO: an R/Bioconductor package providing an AmiGO visualize interface.
Markus S Schröder, Daniel Gusenleitner, John Quackenbush, Aedín C Culhane, Benjamin Haibe-Kains

Bioinformatics· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
iBBiG: iterative binary bi-clustering of gene sets.
Daniel Gusenleitner, Eleanor A Howe, Stefan Bentink, John Quackenbush, Aedín C Culhane

Bioinformatics· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GeneSigDB: a manually curated database and resource for analysis of gene expression signatures.
Aedín C Culhane, Markus S Schröder, Razvan Sultana, Shaita C Picard, Enzo N Martinelli, Daniel Gusenleitner

Nucleic Acids Res· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GCOD - GeneChip Oncology Database.
Fenglong Liu, Joseph A White, Corina Antonescu, Daniel Gusenleitner, John Quackenbush

BMC Bioinformatics· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis